In a recent decision X ZR 89/07 the German Federal Supreme Court (FSC) confirmed the validity of EP 454 436 B1, which is directed to Eli Lilly's neuroleptic drug olanzapine, marketed under the name Zyprexa. In a first instance, the German Federal Patent Court (FPC) declared the patent null and void for lack of novelty. The FPC based its decision on the reasoning of an older FSC decision "Fluoran", in which criteria for novelty of chemical structures had been laid down. According to Fluoran, the decisive question as to whether a compound is considered to be anticipated by a general formula covering it is if a skilled person is able to reduce the invention to practice, that is to synthesise the respective compound. In the Fluoran case this question was answered in the affirmative, although the claimed compound had not been individualised in the reference.